Coupons and vouchers for name-brand prescription drugs claim to cut costly out-of-pocket expenses, but they actually may be doing very little to control prices.
Coupons and vouchers for name-brand prescription drugs claim to cut costly out-of-pocket expenses, but they actually may be doing very little to control prices.
There are several reasons for the absence of actual savings. Most available coupons only cover 3-months’ supply or less of a drug, meaning the remaining refills are at full cost. Switching to a generic form of a brand-name drug is difficult for most patients. Doctors also may not be communicating about lower-cost alternatives to patients.
“Once a coupon program ends, patients with chronic diseases face copayments for these brand-name medications that are higher than those for generic alternatives,” read a recent report. “By that point, however, patients may have developed loyalty to the particular brand or may be skeptical about switching away from a medication that they perceive as effective—or they may not even be aware of alternative therapies.”
As well, because brand-name drugs typically cost more for payers, costs are then passed on to consumers through higher premiums. “The more that patients use drug coupons to obtain brand-name medications when lower-cost alternatives are available,” the report continued, “the more expenses will rise for their insurers. A predictable response from the insurers would be to raise coverage rates for all patients.”
Patients' medication adherence is likely to suffer in the absence of any discounts. Matthew Bennett, senior vice president of the Pharmaceutical Research and Manufacturers of America, says, "Today's high levels of cost sharing can pose a significant access barrier for patients, resulting in low adherence and poor health outcomes."
To ensure medication adherence does not falter due to costs, physicians must ensure consumers are aware of both the benefits and pitfalls of using prescription drug coupons.The report concluded, “Physicians need to talk to their commercially insured patients about the implications of drug-coupon use and make sure that their inclination to reduce short-term out-of-pocket spending doesn’t come at the cost of higher long-term expenses for themselves and society."
Around the Web
Check Up: Prescription-discount Coupons Have Hidden Costs [Philly.com]
Do Prescription Drug Coupons Lead To Higher Insurance Rates For Everyone? [The Consumerist]
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More